A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Clinical trial NCT06608199 · RECRUITING
Trial details
- NCT number
- NCT06608199
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-01
- Primary completion
- 2025-06-01
- Enrollment
- 500
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.